Revenue segments as reported by the company.

Medical Devices

Specialty Pharmaceuticals

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Royalty expense

Amortization expense

Intangible asset impairment charges

Contingent consideration net expense (benefit)

Restructuring net charges (credits)

Litigation-related net charges (credits)

Gain on disposal of businesses and assets

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Boston Scientific

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment consists of technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979, and is headquartered in Marlborough, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Boston Scientific reports solid Q4 performance and eyes global growth

Boston Scientific's Q4 performance was solid, with growth across regions and business units.
Challenges include potential sales growth hurdles in Q1 2023 and headwinds from tough comps and market adjustments.
Opportunities lie in continued momentum in key business units, successful product launches, and global growth prospects.
The company remains focused on sustaining growth, expanding margins, and delivering double-digit adjusted EPS growth.

Boston Scientific surpasses Q1 expectations, eyes growth through Farapulse

Boston Scientific's Q1 '23 earnings call showcased strong performance, with exceeding revenue expectations and solid organic sales growth. The company's strategic focus on high-growth M&A, resolving supply constraints for Farapulse, and capital allocation priorities position it well for future growth. Challenges include potential earnings dilutive deals and addressing free cash flow conversion challenges.

Boston Scientific surpasses Q2 expectations, eyes margin expansion and innovation

Boston Scientific delivered a strong Q2 '23 performance, exceeding expectations with robust sales growth and improved adjusted EPS, driven by strong performance across key regions and business segments.
While facing challenges such as inflation impact and market dynamics, the company remains focused on opportunities for margin expansion, product innovation, and strategic acquisitions to drive future growth.
With a positive outlook for the coronary business, upcoming product launches, and a commitment to operational excellence, Boston Scientific aims to maintain its competitive edge and capitalize on market opportunities.
Anticipated results from trials, market potential for new products, and a focus on sustainable growth strategies position Boston Scientific for continued success and market leadership in the healthcare sector.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities ahead

Boston Scientific's Q3 2023 results exceeded expectations, with strong performance across regions and business units.
The company raised full-year guidance, expecting organic revenue growth of approximately 11% and adjusted EPS range of $1.99 to $2.02.
Challenges in the Neuromodulation business and cost impacts are being addressed for future improvement.
Opportunities lie in acquisitions, FDA approvals, and strategic commercial initiatives for growth and margin expansion.

Boston Scientific (BSX) exceeds Q4 expectations, eyes growth opportunities

Boston Scientific (BSX) reported impressive Q4 2023 results, exceeding sales and EPS guidance.
The company showcased strong regional growth, highlighted key products, and outlined solid 2024 outlook.
While facing challenges like delayed product launches and market disruptions, BSX remains focused on growth opportunities.
Strategic acquisitions and margin improvement initiatives position Boston Scientific for continued success in the future.

Boston Scientific beats Q1 expectations, eyes growth in key markets

Boston Scientific delivered strong Q1 results, exceeding expectations and showcasing growth across key regions and business units.
While facing challenges like inventory charges, the company is focused on leveraging opportunities in expanding product indications and enhancing capabilities.
With raised full-year guidance and a focus on innovation and market expansion, Boston Scientific is poised for continued growth and success in 2024.

Boston Scientific (BSX) reports stellar Q2 results and eyes sustained growth

Boston Scientific's Q2 2024 performance exceeded expectations, showcasing strong financial results and regional sales growth across key markets.
The company's strategic strengths lie in diversified business units, innovative products like FARAPULSE, and strategic acquisitions like Silk Road Medical.
While challenges exist in adoption metrics and margin expansion, BSX's focus on reinvestment and growth opportunities position it well for sustained success.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities in Asia

Boston Scientific's Q3 performance exceeded expectations, driven by strong sales growth and increased adjusted EPS.
The company's focus on innovation and strategic investments in key business units like Cardiology and Neuromodulation bode well for future growth.
Despite challenges in China and the need to deliver on growth targets, Boston Scientific remains confident in its ability to sustain top-tier financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

MARLBOROUGH, Mass., May 27, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) completed the concurrent offerings of (i) 29,382,500 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 3,832,500 additional shares...

Boston Scientific Completes Approximately $2.0 Billion Aggregate Offerings of Common Stock and Mandatory Convertible Preferred Stock

MARLBOROUGH, Mass., May 26, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Jefferies 2020 Virtual Healthcare Conference on June 2. Joe Fitzgerald, executive vice president and president, Rhythm Management; Kenneth Stein, M.D., senior vice...

Boston Scientific to Participate in Jefferies 2020 Healthcare Conference

MARLBOROUGH, Mass., May 21, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced the pricing of concurrent offerings of 25,550,000 shares of its common stock ("Common Stock") at a price to the public of $34.25 per share and 8,750,000 shares of its 5.50% Mandatory...

Boston Scientific Prices Offerings of Common Stock and Mandatory Convertible Preferred Stock

Boston Scientific (NYSE: BSX) shares are trading lower on Thursday. The company announced it has commenced concurrent offerings of $750 million shares of its common stock and $750 million of shares of its Series A Mandatory Convertible Preferred Stock.

Why Boston Scientific's Stock Is Trading Lower Today

MARLBOROUGH, Mass., May 20, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced that it has commenced concurrent offerings of $750.0 million of shares of its common stock ("Common Stock") and $750.0 million of shares of its Series A Mandatory Convertible Preferred...

Boston Scientific Announces Offerings of Common Stock and Mandatory Convertible Preferred Stock

What stocks are most popular among the gurus, the investing giants after whom GuruFocus is named?

Boston Scientific: Fast-Growing Earnings Get the Attention of Gurus

Salesforce

Elanco Animal Health Inc

Fidelity National Information

Lyft

Merck

David Carlson (Trades, Portfolio)’s Elfun Trusts bought shares of the following stocks in both the fourth quarter of 2019 and the first quarter of 2020.

7 Stocks Elfun Trusts Continues to Buy

MARLBOROUGH, Mass., May 18, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) completed a public offering of $1.7 billion aggregate principal amount of its senior notes. The public offering consists of $500.0 million of 1.900% notes due 2025 and $1.2 billion of 2.650% notes...

Boston Scientific Completes $1.7 Billion Offering of Senior Notes

MARLBOROUGH, Mass., May 14, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of $1.7 billion aggregate principal amount of its senior notes under the company's shelf registration statement. The public offering consists of $500.0...

Boston Scientific Prices $1.7 Billion of Senior Notes

Boston Scientific: Start Building A Position In This Beaten-Down Medtech Company

PetIQ

PETQ vs. BSX: Which Stock Is the Better Value Option?

PETQ vs. BSX: Which Stock Should Value Investors Buy Now?

Power Integrations

Trip.com

Investors looking for growth opportunities may want to have a look at the following stocks, as they have a price-earnings ratio below 20 and their trailing 12-month earnings per share have grown.

3 Stocks With Fast-Growing Earnings

But a sharp decline in medical procedures caused a drop in first-quarter profits.

Boston Scientific Stock Rises on Sales Increase, Positive Management Outlook

Boston Scientific Corporation (BSX) CEO Michael Mahoney on Q1 2020 Results - Earnings Call Transcript

Amgen

BioMarin Pharmaceutical

Quest Diagnostics

Owens & Minor

Stryker

In spite of Covid-19 and global recession concerns, we have a positive outlook on the biotechnology sub-industry; we expect to see a ramp-up in new drug sales; the continued development of many new, innovative therapies; and a decline in the prevalence of patent expirations in 2020 and 2021.

CFRA Analysts Highlight 6 Health Sector Buys For Your Portfolio

The severity of the COVID-19 outbreak takes a toll on Boston Scientific's (BSX) global sales during the first quarter.

Boston Scientific (BSX) Q1 Earnings Miss, Margins Decline

Boston Scientific (BSX) delivered earnings and revenue surprises of -15.15% and 0.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Boston Scientific (BSX) Q1 Earnings Miss Estimates

Boston Scientific earnings missed first-quarter estimates while sales were roughly in line. BSX stock was not yet active early Wednesday.

Boston Scientific Earnings Fall Short

Align Technology

Hologic

Labcorp Holdings Inc

Many Medical Product stocks might have succeeded in mitigating coronavirus-led downsides banking on huge market adoption of their COVID-19-related healthcare-support products.

Medical Products Stock Earnings on Apr 29: BSX, ALGN & More

Boston Scientific's (BSX) business trends in the first two months of the quarter in line with its expectations.

Can IC and PI Arms Drive Boston Scientific (BSX) Q1 Earnings?

Baxter

Based on historical performance, Boston Scientific appears to be an attractive bet compared to Baxter International for growth after the current COVID-19 crisis winds down.The current coronavirus crisis will likely impact medical devices companies on two fronts, 1. supply chain disruptions, and.

Sell Baxter International To Buy Boston Scientific?

The company's Coventor will retail for under $1,000.

Boston Scientific Begins Selling Low-Cost Ventilator Alternative

The coronavirus outbreak meant the postponement of medical procedures, weighing on Boston Scientific’s revenue.

Why Boston Scientific Shares Fell 12.7% in March

The company did not offer updated guidance for its full-year fiscal 2020 results.

Boston Scientific Drastically Reduces Q1 Revenue Guidance

Boston Scientific Corp. BSX, -7.48% said Thursday it expects first-quarter revenue growth to be flat to up slightly versus the year-earlier period, after the COVID-19 pandemic caused many elective procedures to be delayed.

News for Boston Scientific Stock (BSX)